Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Lixte Biotechnology Holdings's annualizedNet Income for the quarter that ended in Dec. 2023 was €-3.78 Mil. Lixte Biotechnology Holdings's average total tangible assets for the quarter that ended in Dec. 2023 was €4.43 Mil. Therefore, Lixte Biotechnology Holdings's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -85.46%.
The historical rank and industry rank for Lixte Biotechnology Holdings's Return-on-Tangible-Asset or its related term are showing as below:
FRA:8640'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -504.28 Med: -124.44 Max: -69.62
Current: -112.89
During the past 13 years, Lixte Biotechnology Holdings's highest Return-on-Tangible-Asset was -69.62%. The lowest was -504.28%. And the median was -124.44%.
FRA:8640's Return-on-Tangible-Asset is ranked worse than 82.38% of 1555
companies
in the Biotechnology industry
Industry Median: -39.95
vs FRA:8640: -112.89
Lixte Biotechnology Holdings Return-on-Tangible-Asset Historical Data
The historical data trend for Lixte Biotechnology Holdings's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lixte Biotechnology Holdings's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lixte Biotechnology Holdings Return-on-Tangible-Asset Distribution
For the Biotechnology industry and Healthcare sector, Lixte Biotechnology Holdings's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Lixte Biotechnology Holdings's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2023) net income data.
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Lixte Biotechnology Holdings Return-on-Tangible-Asset Related Terms
Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Lixte Biotechnology Holdings (FRA:8640) Business Description
Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:8640 has been successfully added to your 